{"url_path":"/sec/tara/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1359931/0001213900-26-087506-index.html","accession_number":"0001213900-26-087506","cik":"0001359931","ticker":"TARA","issuer_name":"Protara Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1359931/0001213900-26-087506-index.html","primary_entity_key":"0001359931","primary_entity_name":"Protara Therapeutics, Inc."},"word_count":136,"has_tables":true,"body_markdown":"**Item 2.02. Results of Operations and Financial Condition.**\n\n \n\nOn August 11, 2026, Protara\nTherapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026 in the press release\nattached hereto as Exhibit 99.1 and incorporated herein by reference.\n\n \n\nThe information in this Item\n2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18\nof the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section,\nnor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the\nExchange Act, except as shall be expressly set forth by specific reference in such a filing regardless of any general incorporation language."}